

This PANNA newsletter will also be available at the website: www.pannastudy.com

A newsletter will be issued once per 3 months to update you on the status of the study regarding centres participating and inclusions of patients per drug.

Centres

All centres in *The Netherlands* (RUNMC Nijmegen; Erasmus Rotterdam; AMC Amsterdam) are open for inclusion.

Spain: Badalona is open for inclusion.

UK: all centres (C&W hospital; St Mary's Hospital; St George's hospital) are open for inclusion (also including efavirenz as a compound).

Italy: Rome (National Institute for Infectious Diseases "L. Spallanzani") is open for inclusion.

Germany: National Authority approval, documents have been submitted for ethics approval.

Canada: a grant has been assigned, ethics submission will start.

Portugal: working on submission.

Ireland: working on submission.

Other centres (*Switzerland; France; Belgium; Poland*) will follow and will be contacted by Angela as soon as the above mentioned centres have started.

Inclusions

6 subjects signed informed consent: 2 darunavir; 2 raltegravir; 2 atazanavir. 1 subject delivered prior to curve 3rd trimester.

Next steps

- Contracts between the Radboud University Nijmegen Medical Centre and all the centres participating.
- all countries open in 2010.

Sponsoring

A grant has been assigned from CTN Canada.
BMS has granted sponsoring of PANNA.

List of compounds under investigation

panna

Etravirine, Intelence, TMC125
Emtricitabine, Emtriva or FTC
Tenofovir, Viread, TDF
Atazanavir, Reyataz
Fosamprenavir, Telzir, FPV
Darunavir, Prezista, TMC114
Tipranavir, Aptivus, TPV
Indinavir, Crixivan
Raltegravir, Isentress
Enfuvirtide, Fuzeon
Maraviroc, Celsentri

Efavirenz, Stocrin, EFV; UK only

Investigator Meeting at CROI

21 participants from pharmaceutical industry, PENTA and investigators from 10 study sites were present. Updates on site status and inclusions were given. New ideas came up which will be discussed to include in an amendment: measurement of compounds in breast milk; follow-up the mothers for a longer time period. Presentations can be viewed at:
<http://www.pannastudy.com/main/study-centres>

Angela Colbers
Project manager

E-mail:
A.Colbers@akf.umcn.nl

HIVPharmacology@akf.umcn.nl
Radboud University Nijmegen Medical Centre, Internal postal code 864,
Department of Clinical Pharmacy, P.O. Box 9101, 6500 HB Nijmegen

Phone: + 31 (0)24 - 361 64 05
Fax: + 31 (0)24- 366 87 55